Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3497
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei’s NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. It also discovers and develops pharmaceutical products targeting G protein-coupled receptors. The company provides treatment for Alzheimer’s disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through its office located in London, the UK. Sosei is headquartered in Tokyo, Japan.

Sosei Group Corp (4565) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Partnerships 15
Heptares Therapeutics Enters into Research Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Juntendo University 16
Heptares Therapeutics and PeptiDream Enter into Agreement 17
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 18
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 19
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 20
Jitsubo Enters into Agreement with Heptares Therapeutics 21
Heptares Therapeutics and leadXpro Enter into Agreement 22
Heptares Therapeutics to Form Partnership with Kymab 23
Heptares Therapeutics Enters into Agreement with Pfizer 24
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 25
Sosei Plans to Enter into Agreement with Novartis 26
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 27
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 28
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 29
Heptares Therapeutics Extends Collaboration with the UK Medical Research 30
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 31
Licensing Agreements 32
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 32
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 33
Allergan Amends Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Equity Offering 37
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 42
Asset Transactions 43
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Acquisition 44
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp – Key Competitors 50
Sosei Group Corp – Key Employees 51
Sosei Group Corp – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Financial Announcements 54
Nov 09, 2017: Sosei Group: Consolidated Financial Results for the Second Period FY2017 (IFRS) 54
Corporate Communications 58
Jun 04, 2018: Sosei Announces Appointment of Chris Cargill as Interim CFO 58
Jan 19, 2018: Sosei Group Announces Resignation Of Fiona Marshall As Chief Scientific Officer 59
Jan 19, 2018: Changes in Executive Management at Sosei 60
Product News 61
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 61
Other Significant Developments 62
Feb 02, 2018: Sosei Announces Restatements of Previously Issued Quarterly and Full Year Accounts 62
Jan 26, 2017: Achievement of sales milestone for COPD products 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Heptares Therapeutics Enters into Research Agreement with Imperial College London 15
Heptares Therapeutics Enters into Research Agreement with Juntendo University 16
Heptares Therapeutics and PeptiDream Enter into Agreement 17
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 18
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 19
Pluristem Therapeutics to Partner with Sosei Corporate Venture Capital 20
Jitsubo Enters into Agreement with Heptares Therapeutics 21
Heptares Therapeutics and leadXpro Enter into Agreement 22
Heptares Therapeutics to Form Partnership with Kymab 23
Heptares Therapeutics Enters into Agreement with Pfizer 24
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 25
Sosei Plans to Enter into Agreement with Novartis 26
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 27
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 28
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 29
Heptares Therapeutics Extends Collaboration with the UK Medical Research 30
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 31
Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 32
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 33
Allergan Amends Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
Sosei Group to Raise up to USD199.5 Million in Public Offering of Shares 37
Sosei Group Raises USD33 Million in Private Placement of Shares 38
Sosei Group to Raise USD7 Million in Private Placement of Shares 39
Sosei Group to Raise USD66 Million in Public Offering of Shares 40
Jitsubo to Raise USD1.7 Million in Private Placement 41
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 42
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 43
Formosa Labs Acquires Activus Pharma from Sosei Group 44
Sosei to Acquire 25.6% Stake in MiNA Therapeutics for USD45.2 Million 45
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 47
Sosei Acquires Heptares Therapeutics for USD400 Million 48
Sosei Acquires Stake in Jitsubo for USDUSD1.8 Million 49
Sosei Group Corp, Key Competitors 50
Sosei Group Corp, Key Employees 51
Sosei Group Corp, Other Locations 52
Sosei Group Corp, Subsidiaries 52

List of Figures
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Sosei Group Corp, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cardiovascular Systems Inc (CSII):医療機器:M&Aディール及び事業提携情報
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • Halliburton Co (HAL):企業の財務・戦略的SWOT分析
    Halliburton Co (HAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Origin Energy Limited:企業の戦略・SWOT・財務分析
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd:企業の戦略的SWOT分析
    The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employee …
  • U.S. Geothermal Inc. (HTM):企業の財務・戦略的SWOT分析
    U.S. Geothermal Inc. (HTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Breeze-Eastern Corporation:企業の戦略・SWOT・財務情報
    Breeze-Eastern Corporation - Strategy, SWOT and Corporate Finance Report Summary Breeze-Eastern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Eydo Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eydo Pharma SAS (Eydo Pharma) develops anti-bacterial medicines from essential oils and natural plant molecules for the treatment of infections caused by resistant bacteria. The company developed a pipeline of compounds and formulations such as EP1012, EP1010, EP1011, EP1014, EP1015, EP1020 …
  • Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Orcas Power & Light Cooperative:企業の戦略的SWOT分析
    Orcas Power & Light Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Vitasoy International Holdings Ltd (0345)
    Vitasoy International Holdings Ltd (0345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Carmanah Technologies Corporation:企業の戦略的SWOT分析
    Carmanah Technologies Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Lear Corporation (LEA):企業の財務・戦略的SWOT分析
    Lear Corporation (LEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Profectus BioSciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Profectus BioSciences Inc (Profectus), formerly Maryland Biotherapeutics Inc is a clinical-stage vaccine development company that designs and develops vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. The company's products comprise genevax therapeutic vaccine …
  • Cereno Scientific AB (CRNO TO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cereno Scientific AB (Cereno Scientific) is a developer of preventive drugs that normalize the body's own defense system against blood clots. The company develops drugs in the therapeutic area of thrombosis-related cardiovascular diseases. Its lead product candidate CS1 is being developed fo …
  • Unilab (Philippines) Inc:企業の戦略的SWOT分析
    Unilab (Philippines) Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Steppe Cement Ltd:企業の戦略・SWOT・財務情報
    Steppe Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary Steppe Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • National Gas & Industrial Co (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Lennox International Inc.:企業の戦略・SWOT・財務情報
    Lennox International Inc. - Strategy, SWOT and Corporate Finance Report Summary Lennox International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆